Membrane differential filtration is safe and effective for the long-term treatment of Refsum syndrome - An update of treatment modalities and pathophysiological cognition

Transfusion and Apheresis Science

Volumn 29, Issue 1, 2003, Pages 85-91

  Straube, R ^a   Gackler D ^a   Thiele, A ^a   Muselmann, L ^a   Kingreen, H ^a   Klingel, R ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Lipid apheresis; Lipoproteins; Membrane differential apheresis; Phytanic acid; Picolenic acid; Plasmapheresis; Polyneuropathy; Pristanic acid; Refsum's disease; Retinitis pigmentosa

Indexed keywords

ACID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NIGELLA SATIVA EXTRACT; PHYTANIC ACID; PICOLENIC ACID; PRISTANIC ACID; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; BIOACCUMULATION; BLOOD LEVEL; CASE REPORT; CEREBELLAR ATAXIA; CLINICAL FEATURE; CONFERENCE PAPER; DIET RESTRICTION; DISEASE COURSE; FEMALE; HEART; HUMAN; KIDNEY; LONG TERM CARE; MALNUTRITION; MEMBRANE DIFFERENTIAL FILTRATION; MYELIN SHEATH; PATHOPHYSIOLOGY; POLYNEUROPATHY; REFSUM DISEASE; RETINA; RETINITIS PIGMENTOSA; SAFETY; STORAGE DISEASE; SYMPTOMATOLOGY;

EID: 0038160734     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00102-2     Document Type: Conference Paper

References (14)

1. Kohnen S., Hammerstein W. Refsum syndrome in a pair of monocygote. Ophthamologe. 90(5):1993;519-521.
2. Liebich G.et al. Analysis of polyunsaturated fatty acids in blood serum after fish oil administration. J. Chromatogr. 572:1991;1-9.
3. Verhoeven N.M., Wanders R.J.A., Poll-The B.T., Saudubray J.M., Jakobs C. The metabolism of phytanic and pristanic acid. J. Inher. Metab. Dis. 21:1998;697-728.
4. Marano R., Soliveri P., Garavaglia B., Antonelli A., Girotti F. A case of Refsum disease with atypical clinical picture in family members. Ital. J. Neurol. Sci. 10(4):1989;451-454.
5. Yamamoto S., Onozu H., Yamada N., Hayasaki S., Watanabe A. Mild retinal changes in a 47-year-old patient with phytanic acid storage disease. Ophthalmologica. 209(5):1995;251-255.
6. Levy R., Verny M., Brault J.I., Gugenheim M., Maisonobe T., Leger J.M. Pauci-symptomatic sensory polyneuropathy in Refsum's disease. Rev neurol (Paris). 152(6-7):1996;469-472.
7. Baumgartner M.R., Jansen G.A., Verhoeven N.M., Mooyer P.A., Jakobs C., Roels F.et al. Atypical Refsum disease with pipecolic acidemia and abnormal catalase distribution. Ann. Neurol. 47(1):2000;109-113.
8. Tranchant C., Aubourg P., Mohr M., Rocchicciolöi F., Zaenker C., Warter J.M. A new peroxisomal disease with impaired phytanic and pipecolic acid oxidation. Neurology. 43(10):1993;2044-2048.
9. Wanders R.J., Smit W., Heymans H.S., Schutgens R.B., Barth P.G., Schierbeck H.et al. Age-related accumulation of phytanic acid in plasma from patients with the cerebro-hepato-renal (Zellweger) syndrome. Clin. Chim. Acta. 166(1):1987;45-56.
10. tenBrink H.J., Schor D.S., Kok R.M., Poll-The B.T., Wanders R.J., Jakobs C. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders. J. Lipid. Res. 33(10):1992;1449-1457.
11. Gutsche H.U., Siegmund J.B., Hoppmann I. Lipapheresis, an immunoglobulin-spraing treatment for Refsum's disease. Acta. Neurol. Scand. 94:1996;103-190.
12. Matsuda Y., Malchesky P.S., Nose Y. Assessment of currently available low density lipoprotein apheresis systems. Artif Organs. 18:1994;93-99.
13. Straube R., Gäckler D., Thiele A., Musselmann L., Kingreen H., Klingel R. Membrane differential filtration MDF is safe and effective for the long-term treatment of Refsum's disease. Kidney Blood Pressure Res. 23:2000;214-347.
14. Klenke E, Kahlke W. Über das vorkommen der 3,7,11,15-tetramethylhexadecansäure (phytansäure) in den cholestrinestern und anderen lipidfraktionen der organe bei einem krankheitsfall unbekannter genese (verdacht auf heredopathia atactica polyneuritiformis) (refsum-syndrom). Hoppe Seylers Z. Physiol Chem 1963;333:133-9.